Tampa Bay Gets $47M Radiopharmaceutical Cancer Hub

Florida adults with cancer may gain closer access to radiopharmaceutical therapies as new facilities are built through 2029.

Updated on Nov. 7, 2026 in Diseases

Tampa Bay Gets $47M Radiopharmaceutical Cancer Hub

Live Poll

Should local governments use public money to fund cancer research and biotech companies?

A regional coalition called FORGE received a $47.3 million federal award from the U.S. Economic Development Administration to build a radiopharmaceutical hub in the Tampa Bay area. The coalition, which includes Moffitt Cancer Center and the University of South Florida, will use the funding for five initiatives, including a manufacturing facility and a startup incubator for early-stage life sciences companies.

Why it matters

Radiopharmaceuticals are drugs that deliver radiation directly to cancer cells and are used for both imaging and treatment, so expanding local production capacity could influence how quickly these therapies reach patients in Florida. The project also aims to grow the training pipeline for nuclear pharmacists and imaging technologists, addressing workforce needs in a specialized field.

The figures come from a federal grant award announcement, which documents funding and planned facilities rather than clinical outcomes. No patient-level or treatment-effectiveness data is part of this development.

The players

Moffitt Cancer Center

Tampa-based cancer center known for its research and clinical care in oncology, and the lead partner in the FORGE coalition building the new manufacturing facility.

University of South Florida

Public research university in Tampa with a major academic medical research presence, developing radiochemistry training for nuclear pharmacists through the CORE Select Program.

U.S. Economic Development Administration

Federal agency within the Department of Commerce that funds regional economic development projects, which awarded the $47.3 million to the FORGE coalition.

The details

Radiopharmaceuticals pair a radioactive atom with a targeting molecule that seeks out specific cells, so the radiation is delivered mainly to diseased tissue. Producing these agents requires specialized facilities that can create short-lived isotopes and handle them safely. The planned Integrated Theranostics Center is intended to let scientists produce isotopes and develop therapies for both research and clinical trials, while the coalition's training programs aim to build the staff needed to run them.

Timeline

  1. March: Coalition organizations applied for the federal award.

  2. Q1 or Q2 2028: The FORGE Incubator is expected to open.

  3. Late 2029: The radiopharmaceutical manufacturing facility is expected to be completed.

Health Landscape

Radiopharmaceutical theranostics pair imaging agents with therapeutic ones built on the same targeting principle, and production of the required isotopes has been a constraint on wider availability. Projects like FORGE add regional production capacity to a field that has grown in clinical use in recent years.

If you are facing a cancer diagnosis, the expansion of radiopharmaceutical production could eventually widen access to imaging and therapy options in the region, though the timeline is years away. Anyone with questions about whether a radiopharmaceutical treatment fits their situation should raise them with their oncologist.

The takeaway

Expanding local capacity to produce radiopharmaceuticals is a practical step toward making these cancer tools more available over time. If you want to learn whether a radiopharmaceutical imaging or treatment option is relevant to your care, ask your physician.

What happens next

The FORGE Incubator is expected to open in Q1 or Q2 2028, and the radiopharmaceutical manufacturing facility is expected to be completed by late 2029.

Further reading

For more on the disease at the center of this work, see our Cancer coverage.

Live Poll

Should local governments use public money to fund cancer research and biotech companies?